Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma

Affiliations

• ¹ CCSI, Department of Medicine, Imperial College London, London, UK.
• ² Cancer Research UK Centre for Drug Development, London, UK.
• ³ C&C Management Consulting Ltd, Exmouth, UK.
• ⁴ Alpha Preclinical Consultancy, Halifax, UK.
• ⁵ Independent Consultant, Royston, UK.
• ⁶ In2Phase Ltd, Welwyn Garden City, UK.
• ⁷ Department of Molecular Medicine, University of Naples Federico II, Naples, Italy.
• ⁸ IBB-CNR and CIRPeB, "Federico II" University of Naples, Naples, Italy.
• ⁹ Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
• ¹⁰ DiSTABiF, University of Campania "Luigi Vanvitelli", Caserta, Italy.
• ¹¹ West Middlesex University Hospital, Isleworth, Greater London, UK.
• ¹² Haematology Department, Chelsea and Westminster Hospital, London, UK.
• ¹³ London Haematology Limited, London, UK.
• ¹⁴ Barts Cancer Centre, St Bartholomew's Hospital London, London, UK.
• ¹⁵ Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
• ¹⁶ Royal Free London NHS Foundation Trust, London, UK.
• ¹⁷ Department of Haematology, King's College Hospital, London, UK.
• ¹⁸ Centre for Haematology, Imperial College London, London, UK.
• ¹⁹ Cancer Cell Protein Metabolism, Department of Medicine, Imperial College London, London, UK.